An artificial intelligence (AI) Macular Disease treatment decision tool for patients with wet age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion.

三种常见的疾病影响眼睛后部的中心并导致毁灭性的视力丧失和失明：i）湿性年龄相关性黄斑变性（AMD）; ii）糖尿病性黄斑水肿（DMO）;和iii）。视网膜静脉阻塞（RVO）：最近在眼睛成像和治疗方面的突破已经改变了患有这些疾病的患者的结果，最值得注意的是通过玻璃体内注射。然而，由于我们的人口老龄化和与生活方式有关的疾病如糖尿病的增加，对这些注射的需求急剧增加。因此，没有足够的合格和训练有素的临床医生提供这些重要的治疗。由于患者的延误导致视力丧失病例增加，医疗系统正努力跟上需求。Macusoft将使用先进的软件来自动化和支持患者的治疗建议，使眼科医生能够将更多的时间用于为需要的患者提供视力保护治疗。这将确保更多的患者得到及时治疗，并防止更多的永久性视力丧失。该软件将经过严格的测试，以便我们知道它运行良好，准确和安全。该软件将允许更多的患者得到诊治，帮助负担过重的眼科诊所应对日益增长的服务需求。我们的研究计划是开发该软件，通过对照研究对其进行测试，以便我们知道它运行良好，准确和安全。一旦经过测试，它将在NHS和全球范围内使用，帮助更多的患者接受他们需要的治疗。

Three common diseases affect the centre of the back of the eye and cause devastating loss of vision and blindness: i) wet Age- related Macular Degeneration (AMD); ii) Diabetic Macula Oedema (DMO), and; iii). Retinal Vein Occlusion (RVO).Recent breakthroughs in imaging of the eye and in treatments have transformed the outcome for patients with these diseases, most notably through intravitreal injections. However, there has been a staggering increase in the need for these injections, caused by our ageing population and the rise in lifestyle-related diseases such as diabetes. As a result, there aren't enough qualified and trained clinicians to provide these important treatments. Delays are occurring for patients leading to a rise in cases of sight loss, and health systems are struggling to keep up with demand.Macusoft will use sophisticated software to automate and support the way in which patients are recommended for treatment, enabling ophthalmologists to spend more of their time on administering sight-preserving treatments to patients who need them. This will ensure that more patients are treated in a timely manner, and that more permanent sight loss is prevented. The software will be rigorously tested so that we know it works well, is accurate and is safe.This software will allow more patients to be seen and treated, helping overburdened eye clinics to deal with the increased demand for their services.Our research plan is to develop the software, to test it with a controlled research study so that we know it works well, is accurate and is safe. Once tested it will then be made available for use across the NHS and worldwide, helping many more patients to receive the treatment they need.